Efficacy assessment of interferon-alpha-engineered mesenchymal stromal cells in a mouse plasmacytoma model

Stem Cells and Development

Volumn 20, Issue 4, 2011, Pages 709-719

  Sartoris, Silvia ^a   Mazzocco, Marta ^a   Tinelli, Martina ^b   Martini, Matteo ^a   Mosna, Federico ^b   Lisi, Veronica ^b   Indraccolo, Stefano ^c   Moserle, Lidia ^d   Cestari, Tiziana ^a   Riviera, Anna Pia ^a   Bifari, Francesco ^b   Tridente, Giuseppe ^a   Pizzolo, Giovanni ^b   Krampera, Mauro ^b  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF VERONA   (Italy)

^c VENETO INSTITUTE OF ONCOLOGY IOV IRCCS   (Italy)

^d UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; LENTIVIRUS VECTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; DRUG EFFICACY; GENE THERAPY; IMMUNOHISTOCHEMISTRY; LUNG BLOOD VESSEL; MESENCHYMAL STEM CELL TRANSPLANTATION; MOUSE; NONHUMAN; PLASMACYTOMA; PRIORITY JOURNAL; TUMOR GROWTH; TUMOR MICROENVIRONMENT;

ANIMALS; ANTIGENS, THY-1; APOPTOSIS; BONE MARROW CELLS; CELL LINE, TUMOR; CELL SURVIVAL; COCULTURE TECHNIQUES; GENE THERAPY; INTERFERON-ALPHA; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, INBRED BALB C; NEOPLASM TRANSPLANTATION; NEOVASCULARIZATION, PATHOLOGIC; PLASMA CELLS; PLASMACYTOMA; RECOMBINANT PROTEINS; TRANSPLANTATION, HETEROLOGOUS; TUMOR BURDEN;

MURINAE; MUS;

EID: 79953720285     PISSN: 15473287     EISSN: None     Source Type: Journal    
DOI: 10.1089/scd.2010.0095     Document Type: Article

References (43)

1. Kyle RA and SV Rajkumar. (2006). Monoclonal gammopathy of undetermined significance. Br J Haematol 134: 573-589. (Pubitemid 44255500)
2. Alexanian R and M Dimopoulos. (1994). The treatment of multiple myeloma. N Engl J Med 330:484-489.
3. Attal M, JL Harousseau, AM Stoppa, JJ Sotto, JG Fuzibet, JF Rossi, P Casassus, H Maisonneuve, T Facon, N Ifrah, C Payen and R Bataille. (1996). A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 335:91-97. (Pubitemid 26240110)
4. Kyle RA and SV Rajkumar. (2004). Multiple myeloma. N Engl J Med 351:1860-1873.
5. Richardson PG, P Sonneveld, MW Schuster, D Irwin, EA Stadtmauer, T Facon, JL Harousseau, D Ben-Yehuda, S Lonial, H Goldschmidt, D Reece, JF San-Miguel, J Blade, M Boccadoro, J Cavenagh, WS Dalton, AL Boral, DL Esseltine, JB Porter, D Schenkein and KC Anderson. (2005). Assessment of Proteasome Inhibition for Extending Remissions (APEX) Investigators. Bortezomib or high-dose dexamethasone for relapsed multiple myeloma. N Engl J Med 352: 2487-2498.
6. Barlogie B, J Shaughnessy, G Tricot, J Jacobson, M Zangari, E Anaissie, R Walker and Crowley J. (2004). Treatment of multiple myeloma. Blood 103:20-32. (Pubitemid 38029914)
7. Rosenblatt J and D Avigan. (2008). Cellular immunotherapy for multiple myeloma. Best Pract Res Clin Haematol 21: 559-577.
8. Schaar CG, HC Kluin-Nelemans, C Te Marvelde, S Ie Cessie, WP Breed, WE Fibbe, WA van Deijk, MM Fickers, KJ Roozendaal and PW Wijermans; Dutch-Belgian Hemato- Oncology Cooperative Group HOVON. (2005). Interferonalpha as maintenance therapy in patients with multiple myeloma. Ann Oncol 16:634-639. (Pubitemid 40613331)
9. Kassem M. (2004). Mesenchymal stem cells: biological characteristics and potential clinical applications. Cloning Stem Cells 6:369-374. (Pubitemid 40023491)
10. Krampera M, A Pasini, G Pizzolo, L Cosmi, S Romagnani and F Annunziato. (2006). Regenerative and immunomodulatory potential of mesenchymal stem cells. Curr Opin Pharmacol 6:435-441.
11. Zhao RC, L Liao and Q Han. (2004). Mechanisms of and perspectives on the mesenchymal stem cell in immunotherapy. J Lab Clin Med 143:284-291. (Pubitemid 38586493)
12. Krampera M, S Sartoris, F Liotta, A Pasini, R Angeli, L Cosmi, A Andreini, F Mosna, B Bonetti, E Rebellato, MG Testi, F Frosali, G Pizzolo, G Tridente, E Maggi, S Romagnani and F Annunziato. (2007). Immune regulation by mesenchymal stem cells derived from adult spleen and thymus. Stem Cells Dev 16:797-810. (Pubitemid 350125228)
13. Pereira RF, KW Halford, MD O'Hara, LB Leeper, BP Sokolov, MD Pollard, O Bagasra and DJ Prockop. (1995). Cultured adherent cells from marrow can serve as long-lasting precursor cells for bone, cartilage, and lung in irradiated mice. Proc Natl Acad Sci USA 92:4857-4861.
14. Studeny M, FC Marini, RE Champlin, C Zompetta, IJ Fidler and M Andreeff. (2002). Bone marrow-derived mesenchymal stem cells as vehicles for interferon-b delivery into tumours. Cancer Res 62:3603-3608. (Pubitemid 34728832)
15. Rønnov-Jessen L, OW Petersen, VE Koteliansky and MJ Bissell. (1995). The origin of the myofibroblasts in breast cancer. Recapitulation of tumor environment in culture unravels diversity and implicates converted fibroblasts and recruited smooth muscle cells. J Clin Invest 95:859-873.
16. Karnoub AE, AB Dash, AP Vo, A Sullivan, MW Brooks, GW Bell, AL Richardson, K Polyak, R Tubo and RA Weinberg. (2007). Mesenchymal stem cells within tumour stroma promote breast cancer metastasis. Nature 449:557-563. (Pubitemid 47525152)
17. Bartholomew A, S Patil, A Mackay, M Nelson, D Buyaner, W Hardy, J Mosca, C Sturgeon, M Siatskas, N Mahmud, K Ferrer, R Deans, A Moseley, R Hoffmann and SM Devine. (2001). Baboon mesenchymal stem cells can be genetically modified to secrete human erythropoietin in vivo. Hum Gene Ther 12:1527-1541. (Pubitemid 34248288)
18. Studeny M, FC Marini, JL Dembinski, C Zompetta, M Cabreira-Hansen, BN Bekele, RE Champlin and M Andreeff. (2004). Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J Natl Cancer Inst 96:1593-1603. (Pubitemid 39534883)
19. Sartoris S, MG Testi, E Stefani, R Chignola, C Guerriero, A Matucci, T Cestari, A Scarpa, AP Riviera, G Zanoni, G Tridente and G Andrighetto. (2003). Induction of an antitumour adaptive immune response elicited by tumour cells expressing de novo B7-1 mainly depends on the anatomical site of their delivery. The dose applied regulates the expansion of the response. Immunology 110:474-481. (Pubitemid 37521878)
20. Kö hler G and C Milstein. (1976). Derivation of specific antibody- producing tissue culture and tumor lines by cell fusion. Eur J Immunol 6:511-519.
21. Potter M. (2003). Neoplastic development in plasma cells. Immunol Rev 194:177-195. (Pubitemid 36886436)
22. Roschke V, P Hausner, E Kopantzev, JG Pumphrey, M Riminucci, DM Hilbert and S Rudikoff. (1998). Disseminated growth of murine plasmacytoma: similarities to multiple myeloma. Cancer Res 58:535-541. (Pubitemid 28087419)
23. Glennie S, I Soeiro, PJ Dyson, EW Lam and F Dazzi. (2005). Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105:2821-2827. (Pubitemid 40446275)
24. Krampera M, A Pasini, A Rigo, MT Scupoli, C Tecchio, G Malpeli, A Scarpa, F Dazzi, G Pizzolo and F Vinante. (2005). HB-EGF=HER-1 signalling in bone marrow mesenchymal stem cells: inducing cell expansion and reversibly preventing multi-lineage differentiation. Blood 106: 59-66. (Pubitemid 40967175)
25. Krampera M, L Cosmi, R Angeli, A Pasini, F Liotta, A Andreini, V Santarlasci, B Mazzinghi, G Pizzolo, F Vinante, P Romagnani, E Maggi, S Romagnani and F Annunziato. (2006). Role of the IFN-g in the immunomodulatory activity of human mesenchymal stem cells. Stem Cells 24:386-398. (Pubitemid 44464808)
26. Schnell T, P Foley, M Wirth, J Munch and K Uberla. (2000). Development of a self-inactivating, minimal lentivirus vector based on simian immunodeficiency virus. Hum Gene Ther 11:439-447. (Pubitemid 30101953)
27. Indraccolo S, V Tisato, V Tosello, W Habeler, G Esposito, L Moserle, L Stievano, L Persano, L Chieco-Bianchi and A Amadori. (2005). Interferon-a gene therapy by lentiviral vectors contrasts ovarian cancer growth through angiogenesis inhibition. Hum Gene Ther 16:957-970. (Pubitemid 41153865)
28. Follenzi A, LE Ailles, S Bakovic, M Geuna and L Naldini. (2000). Gene transfer by lentiviral vectors is limited by nuclear translocation and rescued by HIV-1 pol sequences. Nat Genet 25:217-222. (Pubitemid 30394997)
29. Pittenger MF, AM Mackay, SC Beck, RK Jaiswal, R Douglas, JD Mosca, MA Moorman, DW Simonetti, S Craig and DR Marshak. (1999). Multilineage potential of adult human mesenchymal stem cells. Science 284:143-147. (Pubitemid 29282067)
30. Krampera M, S Glennie, J Dyson, D Scott, R Laylor, E Simpson and F Dazzi. (2003). Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigenspecific T cells to their cognate peptide. Blood 101:3722-3729. (Pubitemid 36857965)
31. Peister A, JA Mellad, BL Larson, BM Hall, LF Gibson and DJ Prockop. (2004). Adult stem cells from bone marrow (MSCs) isolated from different strains of inbred mice vary in surface epitopes, rates of proliferation, and differentiation potential. Blood 103:1662-1668. (Pubitemid 38268957)
32. Sudres M, F Norol, A Trenado, S Gregoire, F Charlotte, B Levacher, JJ Lataillade, P Bourin, X Holy, JP Vernant, D Klatzmann and JL Cohen. (2006). Bone marrow mesenchymal stem cells suppress lymphocyte proliferation in vitro, but fail to prevent graft-versus-host disease in mice. J Immunol 176:7761-7767. (Pubitemid 43849077)
33. Ren C, S Kumar, D Chanda, J Chen, JD Mountz and S Ponnazhagan. (2008). Therapeutic potential of mesenchymal stem cells producing interferon-a in a mouse melanoma lung metastasis model. Stem Cells 26:2332-2338.
34. Loebinger MR, A Eddaoudi, D Davies and SM Janes. (2009). Mesenchymal stem cell delivery of TRAIL can eliminate metastatic cancer. Cancer Res 69:4134-4142.
35. Nakamizo A, F Marini, T Amano, A Khan, M Studeny, J Gumin, J Chen, S Hentschel, G Vecil, J Dembinski, M Andreeff and FF Lang. (2005). Human bone marrow-derived mesenchymal stem cells in the treatment of gliomas. Cancer Res 65:3307-3318. (Pubitemid 40524615)
36. Belardelli F, M Ferrantini, E Proietti and JM Kirkwood. (2002). Interferon-a in tumor immunity and immunotherapy. Cytokine Growth Factor Rev 13:119-134.
37. Brassard DL, MJ Grace and RWBordens. (2002). Interferona as an immunotherapeutic protein. J Leukoc Biol 71: 565-581.
38. De Palma M, R Mazzieri, LS Politi, F Pucci, E Zonari, G Sitia, S Mazzoleni, D Moi, MA Venneri, S Indraccolo, A Falini, LG Guidotti, R Galli and L Naldini. (2008). Tumortargeted interferon-a delivery by Tie2-expressing monocytes inhibits tumor growth and metastasis. Cancer Cell 14:299-311.
39. Pfeffer LM, CA Dinarello, RB Herberman, BR Williams, EC Borden, R Bordens, MR Walter, TL Nagabhushan, PP Trotta and S Pestka. (1998). Biological properties of recombinant ainterferons: 40th anniversary of the discovery of interferons. Cancer Res 58:2489-2499. (Pubitemid 28275413)
40. Lokshin A, JE Mayotte and ML Levitt. (1995). Mechanism of interferon b-induced squamous differentiation and programmed cell death in human non-small-cell lung cancer cell lines. J Natl Cancer Inst 87:206-212.
41. Qin XQ, N Tao, A Dergay, P Moy, S Fawell, A Davis, JM Wilson and J Barsoum. (1998). Interferon- b gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice. Proc Natl Acad Sci USA 95:14411-14416. (Pubitemid 28549381)
42. Ozawa S, H Shinohara, HO Kanayama, CJ Bruns, CD Bucana, LM Ellis, DW Davis and IJ Fidler. (2001). Suppression of angiogenesis and therapy of human colon cancer liver metastasis by systemic administration of interferon-a. Neoplasia 3:154-164. (Pubitemid 32410356)
43. Indraccolo S, E Gola, A Rosato, S Minuzzo, W Habeler, V Tisato, V Roni, G Esposito, M Morini, A Albini, DM Noonan, M Ferrantini, A Amadori and L Chieco-Bianchi. (2002). Differential effects of angiostatin, endostatin and interferona1 gene transfer on in vivo growth of human breast cancer cells. Gene Ther 9:867-878. (Pubitemid 34716331)